Introduction
Prostate cancer is the most common malignancy in men and a major cause of cancerrelated deaths. 1 Since prostate-specific antigen (PSA)-based screening regime for prostate cancer remains controversial because of the high rate of overdiagnosis and overtreatment, a validated biomarker to complement PSA for screening and prognostic biomarkers with clinical utility remain an unmet need. 2 In addition to androgens, estrogens also affect prostatic growth and carcinogenesis. 3 The cellular effects of estrogens are mediated by two estrogen receptors (ERs), ERα and ERβ. The human ERα encoding gene locates on chromosome 6q25.1 and consists of eight exons and seven introns. 4 Previous studies showed that the expression of ERα is gradually increased from prostate intraepithelial neoplasia, locally invasive cancers to metastatic lesions at both mRNA and protein levels. 5 Furthermore, in vivo studies submit your manuscript | www.dovepress.com
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Zhao et al using ERα knockout mice revealed that ERα is an important determinant of prostatic carcinogenesis. 3 Although several single nucleotide polymorphisms (SNPs) have been identified in the ERα gene, only a few have been extensively studied in prostate cancer. Furthermore, substantial controversial conclusions have been drawn by these studies. To address these issues, we chose two common polymorphisms in the ERα gene, PvuII (rs2234693 T.C) and XbaI (rs9340799 A.G), and conducted a meta-analysis on case-control studies between prostate cancer patients and prostate cancer-free controls. The aim of this study was to investigate the potential role of ERα PvuII and XbaI polymorphisms in the prostate cancer risk stratification.
Methods
The current meta-analysis was designed and reported according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (Table S1 ). 6 
literature search
Relevant papers published before October 1, 2016, were identified through a literature search in PubMed, Embase, and Cochrane databases using the following strategy: [("gene mutation" OR "polymorphism") OR ("SNP") OR ("genetic variants")] AND [("prostate carcinoma") OR ("prostate neoplasms") OR ("prostate cancer")] AND [("estrogen receptor") OR ("estradiol receptor") OR ("ER") OR ("ESR")]. References from eligible articles were also manually searched to identify other potential publications.
study eligibility
Studies were eligible for inclusion if, 1) studies focused on the association between ERα PvuII and XbaI polymorphisms and the prostate cancer risk; 2) they were case-control clinical studies on human subjects; 3) all diagnoses with prostate cancer were confirmed by pathological or histological examinations and controls were confirmed to be cancer free; 4) sufficient data were provided to estimate crude odds ratios (ORs) with 95% confidence intervals (CIs).
Two authors independently completed the screening process according to the Cochrane Collaboration guidelines. 7 The methodological quality of each retrieved study was assessed using the Strengthening the Reporting of Genetic Association Studies (STREGA) quality score system. 8 Forty-nine assessment items related to the quality appraisal were used in this score system with scores ranging from 0 to 49. Scores of 0-25, 26-37, and 38-49 were defined as low, moderate, and high quality, respectively (Table S2) .
Data extraction
Detailed data from each publication were independently extracted by two authors using a standardized data extraction sheet and were checked by a third author (Table S3) ,50% indicated that heterogeneity among studies was acceptable, and the fixed effects model (the Mantel-Haenszel method) was used. Otherwise, the random effects model (DerSimonian Laird method) was used. Subgroup analyses through ethnicity, country, source of cases and controls, genotype method, and whether HWE was in control or not were also conducted. We also stratified prostate cancer patients according to selected clinical parameters. HWE was evaluated by the χ 2 test in controls. Sensitivity analysis was performed by omitting each study in order to assess the stability of pooled results. Begger's funnel plots and Egger's linear regression test were used to evaluate publication bias. If significant publication bias existed, the trim and fill method was used to adjust pooled estimates. 9 All tests were two sided, and P,0.05 was considered statistically significant. Data analysis was performed using the STATA software (version 12.0; Stata Corp, College Station, TX, USA).
Results
characteristics of included studies
According to the inclusion criteria, 18 case-control studies were included in the current meta-analysis. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The flow chart presenting the selection process is shown in Figure 1 . A total of 3,317 prostate cancer patients and 8,324 controls were included in the synthesis. Years of publications ranged from STREGA scores ranged from 29 to 36, which suggested that all of these studies were qualified to the quantitative synthesis. The characteristics and methodological quality of the included studies are summarized in Tables 1 and S4 . Table 3 ).
Sensitivity analysis suggested that individual studies did not affect pooled ORs ( Figure S1 ). Begger's funnel plot and Egger's linear regression test did not show any statistical evidence of publication bias (Figure 2A ). In addition, we excluded one study that deviated significantly from HWE, as the results showed that this non-HWE study had no effect on pooled ORs ( Figure S2 ). Begger's funnel plot and Egger's linear regression test did not show any statistical evidence of publication bias ( Figure 2B ). Moreover, we excluded two studies that deviated significantly from the HWE test, and the results showed that these two non-HWE studies had no effect on pooled ORs (Table 4) .
Discussion
The role of PSA as a biomarker in prostate cancer remains unsatisfactory, leading to considerable overdiagnoses and overtreatment. This study on novel biomarkers in prostate cancer represents a long-standing hotspot in biomedical research. 28 Since ERα is an important determinant of prostatic carcinogenesis, 3 various studies have focused on SNPs in the ERα gene to determine their possible associations with the prostate cancer susceptibility. In the current study, we chose two common SNPs in the ERα gene, PvuII (rs2234693 T.C) and XbaI (rs9340799 A.G), and conducted a metaanalysis to evaluate their associations with prostate cancer susceptibility.
To our knowledge, the present work represents the largest meta-analysis performed to estimate the association of ERα SNPs with the risk of prostate cancer. The results showed that both PvuII and XbaI polymorphisms were correlated with an increased risk of prostate cancer in Caucasians, but not in Asians, and this disparity might be attributable to discrepancies in racial backgrounds and geography. 14, 29 Furthermore, there was a significant positive correlation of PvuII polymorphism and high Gleason grade cancers (Gleason score $7), which indicated its potential role in prostate cancer malignant transformation. Both PvuII and XbaI polymorphisms lie in intron 1 of the ERα gene, which is part of the A/B domain, the transactivating factor 1. This domain is an important site for stimulating transcription from certain estrogen-responsive promoters. 25 Among the possible explanations as to how these intronic polymorphisms affected prostate cancer risk are that, 1) both polymorphisms may be in linkage disequilibrium with other unknown variants in the gene, which may affect the gene expression or function; 24, 25, 30 2) the alteration of another unidentified gene was adjacent to the ERα gene; 30 transcription through alternative splicing of the mRNA transcript. 24 Although the susceptibility of Caucasians to prostate cancer is known to be much higher than that of Asians, the underlying mechanism remains unknown. 28 Our findings demonstrated the different roles of two ERα SNPs in prostate cancer risk estimation between Caucasians and Asians, indicating the probability of inherited susceptibility to prostate cancer arising from different genomic ERα SNPs, which may help elucidate the pathogenesis of prostate cancer. 
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Several limitations in this meta-analysis should be noted when interpreting our findings. First, the statistical power was still limited in the stratified analysis. Second, heterogeneity between studies was observed, although subgroup analyses were conducted to minimize the perturbation. Third, only published studies in English were included. Published studies in other languages, ongoing studies, and unpublished data were not obtained. Given these limitations, our conclusions should be interpreted cautiously.
Conclusion
In summary, the current meta-analysis demonstrates the different roles of ERα PvuII and XbaI polymorphisms in prostate cancer risk stratification between Caucasians and Asians, indicating the probability of inherited susceptibility to prostate cancer arising from different genomic ERα SNPs, a finding that may help elucidate the pathogenesis of prostate cancer in Caucasians.
